Filtered By:
Drug: Carbidopa/Levodopa

This page shows you your search results in order of date. This is page number 3.

Order by Relevance | Date

Total 49 results found since Jan 2013.

Patient Preferences for Device-Aided Treatments Indicated for Advanced Parkinsons Disease (APD) (P6.391)
Conclusions: Our findings suggest that patients, on average, prefer device aided treatments over oral therapy to improve movement symptoms in advanced PD, and that a portable infusion pump is preferred to DBS. Patient preferences are important and should be considered for therapeutic and access choices in advanced PD.Disclosure: Dr. Marshall has received personal compensation for activities with AbbVie, Inc. as an employee. Dr. Hauber has received research support from AbbVie. Dr. Fairchild has received research support from AbbVie. Dr. Sail has received personal compensation from AbbVie as an employee of the organization.
Source: Neurology - April 3, 2016 Category: Neurology Authors: Marshall, T., Hauber, A. B., Fairchild, A., Sail, K. Tags: Movement Disorders: Parkinson ' s Disease II Source Type: research

FDA Drug Safety Communication: Ongoing Safety Review of Stalevo and possible increased cardiovascular risk
[08-20-2010] The U.S. Food and Drug Administration (FDA) is evaluating clinical trial data that suggest patients taking Stalevo (a combination of carbidopa/levodopa and entacapone) may be at an increased risk for cardiovascular events (heart attack, stroke, and cardiovascular death) compared to those taking carbidopa/levodopa (sold as the combination product, Sinemet).
Source: FDA Center for Drug Evaluation and Research - What's New - March 2, 2016 Category: Drugs & Pharmacology Source Type: news

L-dopa does not add to the success of high-intensity language training in aphasia.
CONCLUSION: High-intensity language training in chronic aphasia may take learning to a ceiling that precludes additive benefits from l-dopa. Effects of l-dopa on post-stroke recovery during less intense treatment in chronic aphasia remain to be evaluated. PMID: 25588456 [PubMed - indexed for MEDLINE]
Source: Restorative Neurology and Neuroscience - January 25, 2016 Category: Neurology Tags: Restor Neurol Neurosci Source Type: research

Holmes’ tremor as a delayed complication of thalamic stroke
We present a 75-year-old man who developed a disabling tremor 1year after a posterolateral thalamic stroke. This tremor had low frequency (3–4Hz), did not disappear on focus and was exacerbated by maintaining a static posture and on target pursuit, which made it very difficult to perform basic functions. MRI demonstrated an old ischemic lesion at the left posterolateral thalamus. Treatment with levodopa led to symptom control. Lesions in the midbrain, cerebellum and thalamus may cause Holmes’ tremor. Delayed onset of symptoms is usually seen, sometimes appearing 2years after the original injury. This may be due to matu...
Source: Journal of Clinical Neuroscience - November 21, 2015 Category: Neuroscience Source Type: research

Parkinsonism, small vessel disease, and white matter disease: Is there a link?
Parkinsonian syndrome is primarily attributed to striato-nigral degeneration as idiopathic Parkinson disease (PD), although it can be caused by white matter (WM) disease as classically seen in vascular parkinsonism (VP). VP clinically manifests as predominant lower extremities involvement and gait impairment with poor response to levodopa and, radiologically, as WM hyperintensities (WMH) that disrupt the striato-nigral pathways. However, brain MRI vascular lesions correlate poorly with clinical manifestations and pathology findings.1
Source: Neurology - November 2, 2015 Category: Neurology Authors: Luca, C. C., Rundek, T. Tags: Parkinson's disease/Parkinsonism, All Cerebrovascular disease/Stroke EDITORIALS Source Type: research

Neuropharmacology of Poststroke Motor and Speech Recovery.
This article summarizes the published literature for pharmacologic agents used for the enhancement of motor and speech recovery after stroke. Amphetamine, levodopa, selective serotonin reuptake inhibitors, and piracetam were the most commonly used drugs. Pharmacologic augmentation of stroke motor and speech recovery seems promising but systematic, adequately powered, randomized, and double-blind clinical trials are needed. At this point, the use of these pharmacologic agents is not supported by class I evidence. PMID: 26522905 [PubMed - in process]
Source: Physica Medica - November 1, 2015 Category: Physics Authors: Keser Z, Francisco GE Tags: Phys Med Rehabil Clin N Am Source Type: research

Neuropharmacology of Poststroke Motor and Speech Recovery
This article summarizes the published literature for pharmacologic agents used for the enhancement of motor and speech recovery after stroke. Amphetamine, levodopa, selective serotonin reuptake inhibitors, and piracetam were the most commonly used drugs. Pharmacologic augmentation of stroke motor and speech recovery seems promising but systematic, adequately powered, randomized, and double-blind clinical trials are needed. At this point, the use of these pharmacologic agents is not supported by class I evidence.
Source: Physical Medicine and Rehabilitation Clinics of North America - October 30, 2015 Category: Rehabilitation Authors: Zafer Keser, Gerard E. Francisco Source Type: research

Successful Management of Hemorrhage-associated Hemiballism after STN DBS with Pallidal Stimulation: A Case Report
Conclusion In our case pallidal DBS was effective in treating hemiballism that arose as a result of traumatic displacement of STN DBS electrodes. Medical management and changes in stimulation parameters failed to produce any significant change in the hemiballism. This report is only the third of its kind in the literature wherein hemiballism arising as a result of STN damage after DBS was successfully treated with pallidal stimulation.
Source: World Neurosurgery - July 10, 2015 Category: Neurosurgery Source Type: research

The effectiveness of dopamine agonists for treatment of neuropsychiatric symptoms post brain injury and stroke.
CONCLUSION: Our systematic review demonstrates an evolving evidence base to suggest some benefits in agitation and aggression, mood and attentional deficits. However, there are key limitations of the studies undertaken to date involving small numbers of participants, heterogeneous outcome measures, and variable study designs. There is a need for on-going large prospective double-blind RCTs in these medications using standardised criteria and outcomes to fully understand their effectiveness in this patient group. PMID: 25850757 [PubMed - as supplied by publisher]
Source: Acta Neuropsychiatrica - April 11, 2015 Category: Psychiatry Tags: Acta Neuropsychiatr Source Type: research

Serotonin syndrome in stroke patients.
Conclusion: Because a considerable number of stroke patients have some limitation in communication, and serotonin syndrome is a potentially life-threatening condition, clinicians should pay particular attention to the potential for development of serotonin syndrome when prescribing these drugs to stroke patients. PMID: 25483226 [PubMed - as supplied by publisher]
Source: Journal of Rehabilitation Medicine - December 12, 2014 Category: Rehabilitation Tags: J Rehabil Med Source Type: research

Dynamics of major histocompatibility complex class II-positive cells in the postischemic brain - influence of levodopa treatment
Conclusions: Results suggest that dopamine signaling is involved in the adaptive immune response after stroke and involves microglia/macrophages.
Source: Journal of Neuroinflammation - August 23, 2014 Category: Neurology Authors: Enida KuricKarsten Ruscher Source Type: research

Gender and Dopaminergic Medication Treatment in Early Parkinson Disease (P3.069)
CONCLUSIONS: Although we did not observe gender differences in the type and dose of dopaminergic treatment in LS-1 participants with early PD, further research is needed to evaluate gender influences on dopaminergic medication treatment in mid- and late-stage PD.Study Supported by: on behalf of the NET-PD LS1 investigators.Disclosure: Dr. Umeh has nothing to disclose. Dr. Pérez has nothing to disclose. Dr. Augustine has nothing to disclose. Dr. Dhall has received personal compensation for activities with UCP Pharma, Impax Pharmaceuticals, and Teva Neuroscience. Dr. Dewey has received personal compensation for activi...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Umeh, C., Perez, A., Augustine, E., Dhall, R., Dewey, R., Mari, Z., Simon, D., Wills, A. M., Christine, C., Schneider, J., Suchowersky, O. Tags: Movement Disorders: Clinical Features of Parkinson ' s Disease Source Type: research

Reduction of rat brain CD8+ T‐cells by levodopa/benserazide treatment after experimental stroke
This study was conducted to investigate if treatment with levodopa, potentially acting as an immunomodulator, affects the T‐cell accumulation in the post‐ischemic brain. Male Sprague–Dawley rats were subjected to transient occlusion of the middle cerebral artery (tMCAO) for 105 min followed by levodopa/benserazide treatment (20 mg/kg/15 mg/kg) for 5 days initiated on day 2 post‐stroke. One week after tMCAO, T‐cell populations were analysed from brains, and levels of interleukin (IL)‐1β, chemokine (C‐X‐C motif) ligand 1, IL‐4, IL‐5, interferon gamma and IL‐13 were analysed. After levodopa/benseraz...
Source: European Journal of Neuroscience - April 1, 2014 Category: Neuroscience Authors: Enida Kuric, Karsten Ruscher Tags: Research Report Source Type: research

Reversal of stroke induced lymphocytopenia by levodopa/benserazide treatment
Abstract: Evidences exist that dopamine is involved in T-cell homeostasis. Here, we investigated if daily treatment with levodopa (20mg/kg)/benserazide (15mg/kg) regulates the number of T-cells in the blood of Sprague Dawley rats subjected to transient occlusion of the middle cerebral artery (tMCAO). T-cells and associated inflammatory cytokines were analyzed in the blood one week after tMCAO. Treatment with levodopa/benserazide completely recovered T-helper cell depletion in animals subjected to tMCAO whereas T-cell associated cytokines remained unaffected after stroke, however, cytokines were downregulated in levodopa tr...
Source: Journal of Neuroimmunology - March 10, 2014 Category: Allergy & Immunology Authors: Enida Kuric, Karsten Ruscher Tags: Short Communications Source Type: research

Dopamine dysregulation syndrome in Parkinson's disease: from clinical and neuropsychological characterisation to management and long-term outcome
Conclusions Clinicians should be aware of risk factors predisposing to DDS. Duodenal levodopa infusion and, less consistently, STN-DBS were more commonly associated with DDS remission. Effective caregiving plays a key role in long-term behavioural outcome.
Source: Journal of Neurology, Neurosurgery and Psychiatry - February 6, 2014 Category: Neurosurgery Authors: Cilia, R., Siri, C., Canesi, M., Zecchinelli, A. L., De Gaspari, D., Natuzzi, F., Tesei, S., Meucci, N., Mariani, C. B., Sacilotto, G., Zini, M., Ruffmann, C., Pezzoli, G. Tags: JNNP Patients' choice, Drugs: CNS (not psychiatric), Parkinson's disease, Stroke, Drugs misuse (including addiction) Movement disorders Source Type: research